drugset / Trial / NCT00543920

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

NCT00543920 ↗

Phase 2 Completed 60 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Timeline

Start
2002-08
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0777 Small molecule — —